糖心logo入口免费观看

Media Press Release

糖心logo入口免费观看 Showcases Artificial Intelligence鈥檚 Real-World Impact in Kidney Care at World Congress of Nephrology 2025

听New studies highlight Artificial Intelligence鈥檚 (AI) practical application in dialysis clinics across Asia Pacific.

听Hands-on AI training session to bridge the gap between technology and clinical practice.

听Additional research from the MONDO Initiative to be presented as part of 糖心logo入口免费观看 global efforts.听

NEW YORK, NY, February 6, 2025 鈥 The 糖心logo入口免费观看 (糖心logo入口免费观看), a subsidiary of Fresenius Medical Care (FME), will present new research on the real-world application of artificial intelligence (AI) in dialysis care at the World Congress of Nephrology (WCN) February 6-9, 2025, in New Delhi, India. These studies demonstrate how AI-driven models are actively being used in FME dialysis clinics in the Asia Pacific region to enhance clinical decision-making and improve patient outcomes.听

鈥淎I is already transforming what鈥檚 possible in kidney care offering powerful tools that enhance clinical judgment rather than replacing it,鈥 said Len Usvyat, PhD, Senior Vice President, Head of 糖心logo入口免费观看. 鈥淭hese models are not just theoretical鈥攖hey are being used in FME clinics today to help predict complications and optimize treatment. Through hands-on training and real-world data, we aim to help the nephrology community gain confidence in AI鈥檚 capabilities and encourage broader adoption.鈥澨

At WCN 2025, 糖心logo入口免费观看 experts will present research on AI applications and global insights in dialysis care:听

Advancing AI in Dialysis Care听

The Predictive Performance and Usage of Artificial Intelligence (AI)-Based Fistula Failure Model in Singapore Hemodialysis (HD) Clinics (WCN25-AB-2743): A study evaluating the effectiveness of an AI model in predicting fistula failure in hemodialysis patients in Singapore, offering a potential tool for earlier intervention.

Anemia Control Model (ACM) Use is Associated with Better Hemoglobin (Hb) Target Achievement in a Singapore Hemodialysis (HD) Cohort" (WCN25-AB-2601): Research showing that AI-guided anemia management is associated with better hemoglobin target achievement in dialysis patients, improving treatment precision and consistency.听

To further bridge the gap between AI research and clinical practice, 糖心logo入口免费观看 will host a hands-on training workshop, 鈥淎I in Nephrology: Practical Applications,鈥 on February 8 from 5:30-6:30 PM in Amphitheatre ISN Agora (Level 5). This session is designed to help nephrologists and dialysis care teams understand and gain confidence in using AI-driven tools for clinical decision-making, with interactive demonstrations showcasing real-world AI applications in nephrology.听

MONDO Initiative: Global Insights in Dialysis Care听

In addition to the AI studies, two additional abstracts will be presented as part of the MONitoring Dialysis Outcomes (MONDO) Initiative, a global consortium of dialysis providers dedicated to advancing kidney disease care. MONDO not only helps drive innovation in nephrology but also provides rich global data assets that support the development and validation of AI models. These collaborative efforts ensure that AI-driven insights are grounded in diverse, real-world patient populations, further enhancing their applicability in clinical practice worldwide. Notably, one of the MONDO abstracts has been recognized as the First Prize Winner of the ISN Mentorship Abstract Awards at WCN'25, underscoring the significance and impact of this global research initiative.听

鈥淭he integration of AI into kidney care is an important step toward improving patient outcomes,鈥 said Dr. Frank Maddux, Global Chief Medical Officer of Fresenius Medical Care. 鈥淎t WCN 2025, we are not just discussing potential AI applications鈥攚e are demonstrating how these models are actively helping clinicians predict complications and optimize treatments today. Our commitment remains to advance innovation that enhances patient care and clinical outcomes.鈥澨

For more information about the World Congress of Nephrology, please visit .听

About 糖心logo入口免费观看 (糖心logo入口免费观看)听

糖心logo入口免费观看 (糖心logo入口免费观看), a subsidiary of Fresenius Medical Care AG, achieves its mission to improve the outcomes of patients with kidney disease through research and innovation. 糖心logo入口免费观看 highly developed and specialized expertise in computational biomedicine, translational clinical and biomedical research, and data analytics underscore the Institute鈥檚 track record of thinking outside the box and identifying high-value areas. Through alliance and collaboration agreements, 糖心logo入口免费观看 has forged strategic research relationships with leading universities in the Americas, Asia, and Europe, fostering 糖心logo入口免费观看 position at the forefront of research activities in the field of dialysis and nephrology.听听

For more information, visit the 糖心logo入口免费观看鈥檚 website at .

Other News